<Industry Awareness and Future Trends> The Reality of Clinical Trial Drug Supply During the COVID-19 Pandemic
A report on a survey conducted with 234 individuals engaged in clinical supply and operations regarding the advantages and potential barriers of DtP in current and future clinical trials.
The ideal model for remote clinical trials such as DtP and StP is to be flexible and accurately address the needs of patients and the protocol. With Catalent's "FlexDirect" Direct-to-Patient service, sponsors can make strategic choices flexibly. In addition to consistent supply support from Catalent, including traditional site shipments, site-to-patient shipments (StP), and direct-to-patient shipments (DtP), customized support for specific needs (such as emergency shipments) is also possible. Patient needs vary each time depending on the situation. This "FlexDirect" Direct-to-Patient service model allows for flexible responses to any situation. More detailed information is also available here: clinical.catalent.com/solutions/flexdirect-direct-to-patient-services/
- Company:キャタレント・ジャパン
- Price:Other